The Pleural Disease drugs in development market research report provides comprehensive information on the therapeutics under development for Pleural Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Pleural Disease. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Pleural Disease and features dormant and discontinued products.
GlobalData tracks 20 drugs in development for Pleural Disease by 21 companies/universities/institutes. The top development phase for Pleural Disease is preclinical with eight drugs in that stage. The Pleural Disease pipeline has 19 drugs in development by companies and one by universities/ institutes. Some of the companies in the Pleural Disease pipeline products market are: Zhejiang Conba Pharmaceutical, Boehringer Ingelheim International and Genelux.
The key targets in the Pleural Disease pipeline products market include Epithelial Cell Adhesion Molecule, Fibroblast Growth Factor Receptor 1, and Fibroblast Growth Factor Receptor 2.
The key mechanisms of action in the Pleural Disease pipeline product include Nuclear Factor Kappa B Inhibitor with one drug in Preclinical. The Pleural Disease pipeline products include ten routes of administration with the top ROA being Oral and ten key molecule types in the Pleural Disease pipeline products market including Small Molecule, and Synthetic Peptide.
Pleural Disease overview
Pleural disorders encompass a spectrum of conditions affecting the protective tissue surrounding the lungs and lining the chest cavity. Within this category, three distinct types emerge—namely pleurisy, pleural effusion, and pneumothorax—each with diverse etiologies. Characterized by inflammation of the pleura, pleurisy stands as a primary manifestation. Conversely, pleural effusion and pneumothorax result from factors such as infection, medical conditions, or chest trauma, leading to the accumulation of fluid, pus, blood, or air or other gases within the pleural space. Common symptoms across all types include chest pain, shortness of breath, and coughing. Treatment approaches vary based on the specific disorder and its severity. Neglected, pleural disorders pose severe risks, potentially culminating in lung collapse, shock, or sepsis.
For a complete picture of Pleural Disease’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
